Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (31)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Frickhofen, N.
Right arrow Articles by Sigmund, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frickhofen, N.
Right arrow Articles by Sigmund, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:797-801, 2002
© 2002 European Society for Medical Oncology

Clinical Investigations

Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil

N. Frickhofen1,+, F.-J. Beck2, B. Jung1, H.-G. Fuhr1, H. Andrasch3 and M. Sigmund2

1Department of Hematology/Oncology and 2Department of Cardiology, HSK, Dr-Horst-Schmidt-Kliniken, Wiesbaden; 3Internal Medicine Office, Wiesbaden, Germany

Received 5 July 2001; accepted 20 July 2001.

Abstract

Capecitabine is a member of a new class of oral fluoropyrimidines. It is a 5-fluorouracil (5-FU) prodrug, activated by a series of enzymes. Activation has been demonstrated to occur preferentially in tumor tissue, which may explain the favorable balance of efficacy and toxicity of this drug. Cardiotoxicity, a rare but potentially serious adverse effect of 5-FU, has not been reported for capecitabine to date. Here we report a patient who experienced a severe and prolonged acute coronary syndrome during treatment with capecitabine. He had previously developed similar symptoms during treatment with infusional 5-FU. Capecitabine should thus be considered an agent with cardiotoxic potential. This adverse effect should be specifically monitored in all patients treated with capecitabine. Patients with symptoms suggestive of cardiotoxicity during previous treatment with a fluoropyrimidine should not be treated with capecitabine.

Key words: adverse effects, capecitabine, cardiotoxicity, case report, chemically induced, thymidine phosphorylase


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Emerg. Med. J.Home page
C A Papadopoulos and H Wilson
Capecitabine-associated coronary vasospasm: a case report
Emerg. Med. J., May 1, 2008; 25(5): 307 - 309.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Floyd, D. T. Nguyen, R. L. Lobins, Q. Bashir, D. C. Doll, and M. C. Perry
Cardiotoxicity of Cancer Therapy
J. Clin. Oncol., October 20, 2005; 23(30): 7685 - 7696.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
O. Pagani, C. Sessa, F. Nole, E. Munzone, D. Crivellari, D. Lombardi, B. Thurlimann, D. Hess, R. Graffeo, M. Ruggeri, et al.
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
Ann. Onc., October 1, 2005; 16(10): 1609 - 1617.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
N. Meydan, I. Kundak, T. Yavuzsen, I. Oztop, S. Barutca, U. Yilmaz, and M. N. Alakavuklar
Cardiotoxicity of de Gramont's Regimen: Incidence, Clinical Characteristics and Long-term Follow-up
Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 265 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Coward, N. Maisey, and D. Cunningham
The effects of capecitabine in Raynaud's disease: a case report
Ann. Onc., May 1, 2005; 16(5): 835 - 836.
[Full Text] [PDF]

Home page
 JCOHome page
A. Hamilton and G. Hortobagyi
Chemotherapy: What Progress in the Last 5 Years?
J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. Aksoy, B. Karaca, M. Dincer, and S. Yalcin
Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient
Ann. Pharmacother., March 1, 2005; 39(3): 573 - 574.
[Full Text] [PDF]

Home page
 CirculationHome page
E. T.H. Yeh, A. T. Tong, D. J. Lenihan, S. W. Yusuf, J. Swafford, C. Champion, J.-B. Durand, H. Gibbs, A. A. Zafarmand, and M. S. Ewer
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Circulation, June 29, 2004; 109(25): 3122 - 3131.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. Kurt, O. O. Eren, H. Engin, and N. Guler
Tumor lysis syndrome following a single dose of capecitabine
Ann. Pharmacother., May 1, 2004; 38(5): 902 - 902.
[Full Text] [PDF]

Home page
 Ann OncolHome page
T. Sudhoff, M.-D. Enderle, M. Pahlke, C. Petz, C. Teschendorf, U. Graeven, and W. Schmiegel
5-Fluorouracil induces arterial vasocontractions
Ann. Onc., April 1, 2004; 15(4): 661 - 664.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.